Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Anti-Coagulants - China

China
  • The Anti-Coagulants market in China is expected to witness significant growth in the coming years.
  • By 2024, the revenue in this market is projected to reach US$3.59bn.
  • This growth is expected to continue with an annual growth rate of 8.07% from 2024 to 2029.
  • As a result, the market volume is estimated to reach US$5.29bn by 2029.
  • When compared globally, it is noteworthy that United States is expected to generate the highest revenue in the Anti-Coagulants market.
  • In 2024 alone, the revenue United States is projected to be a staggering US$16.74bn.
  • China's market for anti-coagulants is witnessing a surge in demand due to the rising prevalence of cardiovascular diseases in the country.

Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson

In-Scope

  • Blood clotting inhibitors

Out-Of-Scope

  • Anti-fibrinolytics
  • Anti-hypertensives
  • Other hematology drugs
  • Other anti-thrombotic agents, such as platelet aggregation inhibitors
  • Thrombolytic drugs
Anti-Coagulants: market data & analysis - Cover

Market Insights report

Anti-Coagulants: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    The use of Anti-Coagulants in China has been on the rise in recent years, driven by factors such as an aging population and increasing incidence of cardiovascular diseases.

    Customer preferences:
    Chinese patients are increasingly opting for Anti-Coagulants as a preventative measure against blood clots, which can lead to serious health complications such as stroke and heart attack. Additionally, many patients are choosing Anti-Coagulants over traditional blood thinners due to their convenience and ease of use.

    Trends in the market:
    The Anti-Coagulants market in China is expected to continue growing in the coming years, driven by an aging population and increasing incidence of cardiovascular diseases. Additionally, the market is expected to see increased competition as new players enter the market and existing players expand their product offerings.

    Local special circumstances:
    China has a large and growing population of elderly citizens, who are at a higher risk for cardiovascular diseases and blood clots. Additionally, the Chinese government has been investing heavily in healthcare infrastructure and increasing access to healthcare services, which has led to increased demand for Anti-Coagulants and other preventative medicines.

    Underlying macroeconomic factors:
    China's rapidly growing economy and increasing middle class have led to increased healthcare spending and greater demand for high-quality medical treatments. Additionally, the Chinese government has implemented policies to encourage the development of the pharmaceutical industry and increase access to healthcare services, which has led to increased investment in research and development of new Anti-Coagulants and other medicines.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Anti-Coagulants: market data & analysis - BackgroundAnti-Coagulants: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.